13D Filing: SC Fundamental Value Fund, L.P. and Aviragen Therapeutics Inc. (AVIR)

CUSIP No. 053761102

13D/A

Page 9 of 11 Pages

ITEM
1. Security and Issuer

(a)

The name of the issuer is Aviragen Therapeutics, Inc. (AVIR) (the “Issuer”).

(b)

The address of the Issuer’s principal executive offices is 2500 Northwinds Parkway, Suite 100, Alpharetta, Georgia 30009.

This
Schedule 13D/A (the “Schedule”) relates to the common stock (“Common Stock”), of the Issuer.

This
Schedule 13D/A constitutes Amendment No. 2 to the Schedule 13D (this “Amendment”) relating to the Common Stock
of the Issuer and hereby amends the Schedule 13D/A filed with the Securities and Exchange Commission on November 8, 2017 (the
“November Schedule 13D”), on behalf of the Reporting Persons. This Amendment amends Items 3, 4 and 5 and constitutes
the exit filing of the Reporting Persons. Except as set forth herein, this Amendment does not supplement, restate or amend any
of the other information disclosed in the November Schedule 13D.

 

ITEM 3. Source and Amount of Funds or Other Consideration

Item 3 is amended to add the following:

The Fund
has sold in the past sixty days an aggregate of 561,721 shares of Common Stock of the Issuer for total consideration of $387,513.78.

 

ITEM
4. Purpose of Transaction

Item
4 is amended to add the following: 

The Reporting
Persons continue to oppose the proposed merger of the Issuer and Vaxart, Inc. for reasons described in the November 13-D. As also
described in that 13-D, the Reporting Persons indicated they might sell their shares of the Issuer’s Common Stock at prices approaching
the Reporting Persons’ assessment of liquidation value. Due to the Reporting Persons’ sales, their collective beneficial ownership
of shares of the Issuer’s Common Stock fell below 5% and they are no longer subject to the reporting obligations of Rule 13d of
the Exchange Act.